Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 [Seeking Alpha]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Seeking Alpha
Revuforj's 4Q25 net revenue surged 38% QoQ to $44M, while Niktimvo delivered $56M, underscoring robust adoption in underserved patient populations. SNDX maintains a solid $394M cash position, supporting ongoing clinical trials and pipeline expansion, though competition from Komzifti introduces new risks. Valuation remains elevated at 10.3x forward EV/sales, reflecting high market confidence in revenue durability but embedding execution risk as SNDX targets profitability. Halfpoint/iStock via Getty Images Thesis: Preliminary 2025 results indicate continued momentum Syndax Pharmaceuticals ( SNDX ) recently announced some preliminary FY25 financial results, and I have to say, they do show some decent commercial and operational progress. The main highlights are the This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SNDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech SummitGlobeNewswire
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Mizuho from $410.00 to $600.00. They now have an "outperform" rating on the stock.MarketBeat
- Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 2/10/26 - Form 4
- 2/10/26 - Form 4
- 2/9/26 - Form 144
- SNDX's page on the SEC website